Amgen (AMGN)
(Delayed Data from NSDQ)
$325.40 USD
+3.49 (1.08%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $324.67 -0.73 (-0.22%) 4:24 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$325.40 USD
+3.49 (1.08%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $324.67 -0.73 (-0.22%) 4:24 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Zacks News
Can Dogs of the Dow ETFs Snap Losing Trend in 2024?
by Sanghamitra Saha
The Dogs of the Dow underperformed the broader market in 2023. However, with the Fed likely to cut rates in 2024, can these dividend dogs roar next year?
Amgen (AMGN) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
Amgen (AMGN) reachead $275.48 at the closing of the latest trading day, reflecting a +0.01% change compared to its last close.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Amgen's (AMGN) Tarlatamab BLA Gets FDA Priority Tag for SCLC
by Zacks Equity Research
Amgen's (AMGN) BLA for tarlatamab to treat advanced small cell lung cancer gets FDA's priority review. A decision is expected on Jun 12, 2024.
Vertex (VRTX) Soars 13.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Vertex (VRTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Amgen (AMGN) reachead $273.99 at the closing of the latest trading day, reflecting a +0.68% change compared to its last close.
Here's Why Amgen (AMGN) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
by Zacks Equity Research
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $269.35, marking a -0.56% move from the previous day.
3 Top Dividend Stocks to Maximize Your Retirement Income
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Pfizer (PFE) Stock Down 5% as Obesity Drug Fails in Phase II
by Zacks Equity Research
The failure of the phase IIb study on danuglipron is a significant blow to Pfizer's (PFE) efforts to take a share of the growing market of GLP-1 drugs for treating obesity.
Why Is BioMarin (BMRN) Up 14.3% Since Last Earnings Report?
by Zacks Equity Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Amgen (AMGN) Up 2.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights McDonald's, Amgen, NextEra Energy, General Mills and Take-Two Interactive Software
by Zacks Equity Research
McDonald's, Amgen, NextEra Energy, General Mills and Take-Two Interactive Software are included in this Analyst Blog.
Amazon (AMZN) Teams Up With Amgen, Expands Customer Base
by Zacks Equity Research
Amazon's (AMZN) AWS gets selected by Amgen. This highlights the efficiency and reliability of AWS' innovative cloud products and services.
Top Stock Reports for McDonald's, Amgen & NextEra Energy
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including McDonald's Corporation (MCD), Amgen Inc. (AMGN) and NextEra Energy, Inc. (NEE).
Is Trending Stock Amgen Inc. (AMGN) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHD
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is First Trust Dow 30 Equal Weight ETF (EDOW) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EDOW